Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) saw unusually-high trading volume on Friday . Approximately 81,232 shares traded hands during trading, an increase of 49% from the previous session’s volume of 54,426 shares.The stock last traded at $9.65 and had previously closed at $9.59.

OXFD has been the topic of several analyst reports. Zacks Investment Research raised shares of Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, May 4th. BTIG Research reissued a “buy” rating and set a $17.00 price target on shares of Oxford Immunotec Global PLC in a research report on Tuesday. Finally, Piper Jaffray Cos. reissued a “buy” rating on shares of Oxford Immunotec Global PLC in a research report on Sunday, June 26th.

The stock’s 50 day moving average price is $8.83 and its 200 day moving average price is $9.77. The stock’s market cap is $218.24 million.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last issued its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.04. During the same quarter in the previous year, the business earned ($0.33) earnings per share. The business earned $19.20 million during the quarter, compared to the consensus estimate of $18.10 million. The firm’s revenue was up 34.3% compared to the same quarter last year. Equities analysts predict that Oxford Immunotec Global PLC will post ($1.28) earnings per share for the current year.

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.